184 related articles for article (PubMed ID: 24755548)
1. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
[TBL] [Abstract][Full Text] [Related]
3. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.
Popova SN; Bergqvist M; Dimberg A; Edqvist PH; Ekman S; Hesselager G; Ponten F; Smits A; Sooman L; Alafuzoff I
Histopathology; 2014 Feb; 64(3):365-79. PubMed ID: 24410805
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.
Lu G; Chang JT; Liu Z; Chen Y; Li M; Zhu JJ
Mol Neurobiol; 2016 Nov; 53(9):6511-6525. PubMed ID: 26614510
[TBL] [Abstract][Full Text] [Related]
6. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
7. GNG5 is an unfavourable independent prognostic indicator of gliomas.
Yang B; Han ZY; Wang WJ; Ma YB; Chu SH
J Cell Mol Med; 2020 Nov; 24(21):12873-12878. PubMed ID: 33000557
[TBL] [Abstract][Full Text] [Related]
8. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
[TBL] [Abstract][Full Text] [Related]
9. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.
Yan W; Zhang W; You G; Zhang J; Han L; Bao Z; Wang Y; Liu Y; Jiang C; Kang C; You Y; Jiang T
Neuro Oncol; 2012 Dec; 14(12):1432-40. PubMed ID: 23090983
[TBL] [Abstract][Full Text] [Related]
10. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
11. Molecular classification of diffuse gliomas.
Jakovlevs A; Vanags A; Gardovskis J; Strumfa I
Pol J Pathol; 2019; 70(4):246-258. PubMed ID: 32146793
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
[TBL] [Abstract][Full Text] [Related]
13. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.
Zhang JX; Han L; Bao ZS; Wang YY; Chen LY; Yan W; Yu SZ; Pu PY; Liu N; You YP; Jiang T; Kang CS;
Neuro Oncol; 2013 Dec; 15(12):1595-603. PubMed ID: 24203894
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.
Natesh K; Bhosale D; Desai A; Chandrika G; Pujari R; Jagtap J; Chugh A; Ranade D; Shastry P
Neoplasia; 2015 Feb; 17(2):225-37. PubMed ID: 25748242
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
Szeliga M
Neurochem Int; 2022 Feb; 153():105256. PubMed ID: 34968631
[TBL] [Abstract][Full Text] [Related]
16. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
17. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
18. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.
Trabelsi S; Chabchoub I; Ksira I; Karmeni N; Mama N; Kanoun S; Burford A; Jury A; Mackay A; Popov S; Bouaouina N; Ben Ahmed S; Mokni M; Tlili K; Krifa H; Yacoubi MT; Jones C; Saad A; H'mida Ben Brahim D
Mol Neurobiol; 2017 May; 54(4):2381-2394. PubMed ID: 26957305
[TBL] [Abstract][Full Text] [Related]
19. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
Nutt CL; Mani DR; Betensky RA; Tamayo P; Cairncross JG; Ladd C; Pohl U; Hartmann C; McLaughlin ME; Batchelor TT; Black PM; von Deimling A; Pomeroy SL; Golub TR; Louis DN
Cancer Res; 2003 Apr; 63(7):1602-7. PubMed ID: 12670911
[TBL] [Abstract][Full Text] [Related]
20. The landscape of the mesenchymal signature in brain tumours.
Behnan J; Finocchiaro G; Hanna G
Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
